<DOC>
	<DOCNO>NCT03069495</DOCNO>
	<brief_summary>This study evaluate blood type 2 innate lymphoid cell participant mild moderate asthma participant chronic urticaria compare healthy adult participant .</brief_summary>
	<brief_title>Role Circulating Innate Lymphoid Cells Allergic Disorders</brief_title>
	<detailed_description>The first objective study determine whether blood ILC2s differ female vs. male allergic asthmatic . This females become susceptible asthma puberty experience severe disease adult . The second objective study determine whether ILC2 cell chronic urticaria differ healthy control . There one share healthy control adult subject group comparison objective 1 2 . In study , blood draw 3 different adult population age 19-50 year : 1 ) Participants mild-to moderate allergic asthma ; 2 ) Participants chronic urticaria , 3 ) Healthy control adult participant . Demographics allergy indicator collect medical chart . The investigator acquire whole blood serum acquisition specific lymphocyte population . There intervention research follow .</detailed_description>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>1 . Adult subject age 1950 year . 2 . Nonsmokers , define &lt; 100 cigarette lifetime . 1 . Female donor exclude menopausal undergone total abdominal hysterectomy and/or bilateral salpingoophorectomy 2 . For female donor , blood draw occur menstrual period time . Subjects exclude menstrual period time blood draw . 3 . Current past smoker . 4 . Subjects asthma lung disease include chronic obstructive pulmonary disease , interstitial lung disease , pulmonary hypertension , sarcoidosis , cystic fibrosis . 5 . Pregnant lactating subject 6 . Subjects hypercalcemia ( &gt; 10.3 mg/dL ) , renal insufficiency ( glomerular filtration rate [ GFR ] &lt; 50 mL/min/1.73m2 ) , malignancy . 7 . Subjects symptoms respiratory infection past 4 week . 8 . Subjects unable hold leukotriene modifier antihistamines least 24 hour prior blood draw . 9 . Subjects immunomodulators , include omalizumab , systemic corticosteroid past 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Asthma</keyword>
	<keyword>Urticaria</keyword>
</DOC>